Indications for Elotuzumab

Elotuzumab (Elotuzumab) is a targeted immunostimulatory antibody that specifically acts on the SLAMF7 molecule and is mainly used to treat multiple myeloma (MM). This drug enhances the anti-tumor effect of natural killer cells (NK cells) in the body by binding to specific receptors in the immune system, thereby helping patients fight malignant tumor cells in the bone marrow. Multiple myeloma is a malignant plasma cell proliferative disease that often causes symptoms such as bone pain, anemia, and renal damage. Due to its remarkable efficacy, evolizumab has become an important drug in the treatment of multiple myeloma.

The indications of evolizumab mainly include the following two treatment options:

1. Combined treatment with lenalidomide and dexamethasone is suitable for adult patients with multiple myeloma who have received 1 to 3 treatments. The combination can continue to effectively control the disease after conventional treatment and delay further progression of the disease.

2. Combined treatment with pomalidomide and dexamethasone is suitable for patients with multiple myeloma who have received at least two treatments, including patients who have used lenalidomide and proteasome inhibitors. For these refractory or relapsed patients, evolizumab can provide additional treatment options to help improve patients' quality of life and extend survival.

Evolizumab has a unique mechanism that enhances immune surveillance of myeloma cells by activating natural killer cells in the body, effectively slowing down the growth and metastasis of tumors. Evolizumab combined with other drugs has become an important treatment option for patients with multiple myeloma, especially those who have failed or relapsed with conventional treatments.

In short, evolizumab, as an innovative immunotherapy, has shown good clinical prospects in the treatment of multiple myeloma. Especially when combined with other drugs, it can effectively improve the therapeutic effect and provide a new treatment option for patients with multiple myeloma.

Reference materials:https://www.empliciti.com/